Trial · NCT07328022
Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis
NCT07328022, Phase 3, Completed, Laboratorios Silanes S.A. de C.V.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis. Trials, record NCT07328022. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07328022
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Etoricoxib/Betamethasone Combination in Acute Bursitis, Tendinitis and Synovitis
- NCT number
- NCT07328022
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 89 participants, actual
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.
- Conditions
- Bursitis, Tendinitis, Synovitis
- Interventions
- Fixed Dose Etoricoxib + Betamethasone, Monotherapy Etoricoxib
- First posted
- 2026-01-08
- Last updated
- 2026-01-08
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in pain during active movement of the affected joint (VAS 100 mm) at Days 3, 7, 10, and 14 vs baseline, by treatment group. | Baseline and Days 3, 7, 10, and 14 | Pain intensity during active movement will be assessed using a 100-mm Visual Analog Scale (VAS) to determine whether the fixed-dose combination etoricoxib/betamethasone produces a greater reduction in pain compared with etoricoxib alone. Assessments will be obtained at baseline and at follow-up timepoints. |
| Primary | Number of participants with adverse events, and comparison of adverse event frequency and intensity, by treatment group. | Up to 14 days | Safety will be assessed by comparing adverse events occurring during the study between treatment groups. Adverse events will be summarized using frequencies and percentages and classified according to seriousness/gravity, severity, and causality. |
| Secondary | Baseline sociodemographic, anthropometric, biochemical, and clinical characteristics, by treatment group. | Baseline | Descriptive summary of participant characteristics at baseline by randomized group. |
| Secondary | Daily change in maximum pain during active movement of the affected joint (VAS 100 mm) over 14 days vs baseline, by treatment group. | Daily through Day 14 | Patients will record daily VAS scores to estimate the magnitude of change from baseline in maximum pain during active movement throughout treatment. |
| Secondary | Daily change in maximum pain at rest of the affected joint (VAS 100 mm) over 14 days vs baseline, by treatment group. | Daily through Day 14 | Patients will record daily VAS scores at rest to estimate the magnitude of change from baseline throughout treatment |
| Secondary | Clinical improvement using the Clinical Global Impression (CGI) scale at Days 7 and 14 vs baseline, by treatment group. | Baseline, Day 7, and Day 14 | Clinical improvement will be evaluated using CGI (severity/improvement categories) at follow-up and compared with baseline by treatment group. |
| Secondary | Change in Patient Global Assessment of current condition at Days 7 and 14 vs baseline, by treatment group. | Baseline, Day 7, and Day 14 | The Patient Global Assessment will be recorded and changes from baseline will be described by treatment group. |
| Secondary | Proportion of patients by category on the Patient Global Assessment at Days 7 and 14 vs baseline, by treatment group. | Baseline, Day 7, and Day 14 | Changes in the proportion of patients reporting feeling very well, well, fair, poor, or very poor will be summarized by group. |
| Secondary | Change in Investigator Global Assessment at Days 7 and 14 vs baseline, by treatment group. | Baseline, Day 7, and Day 14 | The Investigator Global Assessment will be recorded and changes from baseline will be described by treatment group. |
| Secondary | Proportion of patients by category on the Investigator Global Assessment at Days 7 and 14 vs baseline, by treatment group. | Baseline, Day 7, and Day 14 | Changes in the proportion of participants classified as very well, well, fair, poor, or very poor by the investigator will be summarized by group. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07328022
GET https://conductscience.org/api/trials/v1/NCT07328022/registered